摘要
为观察调肝导浊中药对血载脂蛋白的含量及肝细胞膜脂蛋白受体的影响 ,采用高胆固醇饮食造成动脉粥样硬化家兔模型 ,用免疫比浊法测定载脂蛋白AI和载脂蛋白B含量。体外培养大鼠肝细胞 ,将氧化型低密度脂蛋白直接加入培养液 ,采用原位杂交技术观察它对肝细胞膜脂蛋白受体的影响及调肝导浊中药对其的调节作用。结果发现 ,调肝导浊中药可有效升高载脂蛋白AI含量和降低载脂蛋白B含量。提示调肝导浊中药对脂蛋白受体途径具有良好的调节作用 ,可有效调节与脂质代谢密切相关的因素 ,从而防治高脂血症 。
Aim To observe the effect of liver regulating and turbid removing Chinese medicine formular to apolipoprotein content in blood and lipoprotein receptor in membrane of hepatocyte and research the principle of preventing and curing atherosclerosis. Methods The rabbits were fed with heavy dosage of cholesterol in order to obtain the mould of atherosclerosis by assaying the content of apolipoprotein AI and apolipoprotein B in blood. In addition, the hepatocyte of rat was cultured in vitro by adding ox LDL into the culture medium, and the effect of lipoprotein receptor and the regulating function of Chinese medcine formular related with given in different ways by means of hybridization in situ were observed. Results and Conclusions Liver regulating and turbid removing Chinese medicine formular can increase effectively the content of apolipoprotein AI, decrease that of apolipoprotein B and have a good regulating function about the lipoprotein receptor or passway. Consequently, liver regulating and turbid removing Chinese medicine formular can regulate the factors related with lipid metabolism, thus effectively prevent the formation and progress of hyperlipemia.
出处
《中国动脉硬化杂志》
CAS
CSCD
2002年第3期228-230,共3页
Chinese Journal of Arteriosclerosis
关键词
调肝导浊中药
载脂蛋白
脂蛋白受体
动脉粥样硬化
原位杂交
Chinese Medicine
Apolipoproteins
Receptors, Lipoprotein
Atherosclerosis
Hybridization in Situ
